Email : info@nexusalliancebiopharma.com
Contact : (321) 445-1969

SCP- Oncology

  • Dose escalation to almost 10-20 X of the current SOC- dose regiment, as needed.
  • Combination therapy with other neoplastic with no fear of adverse events of special interests with a clean safety profile.
  • Multiple dose regiment and adjuvant therapy, way beyond the current expected SOC- scheduling.
  • More than 20- 100X of benefit risk ratio; especially, among rare tumors and Relapsed/Refractory with no alternate treatment population.
  • A clear alternative to the high cost, low therapeutic return, and traditionally non- specific current therapy for many population who have failed the traditional cytotoxins.